Skip to main content
RT @RichardPAConway: Pedersen @EBRheum et al. 203 RCTs, 35 (17.2%) remained unpublished more than 30 months after comple

Richard Conway RichardPAConway

3 years 11 months ago
Pedersen @EBRheum et al. 203 RCTs, 35 (17.2%) remained unpublished more than 30 months after completion. Cited reasons: ongoing preparation/review of paper (50%), sponsor/funder problems (40%), unimportant/negative result (20%).@RheumNow #ACR22 Abstr#0827 https://t.co/V2a48iiAcn https://t.co/FLqQhjvlOx
RT @Yuz6Yusof: #ACR22 Abstr#0825 Can we identify predictors of deaths in patients presenting with Macrophage Activation

Md Yuzaiful Md Yusof Yuz6Yusof

3 years 11 months ago
#ACR22 Abstr#0825 Can we identify predictors of deaths in patients presenting with Macrophage Activation Syndrome? A cohort study (N=43) reported MAS was mostly secondary to disease. 10/43 died. Super high Ferritin and raised Ferritin/CRP ratio were assoc with deaths @RheumNow https://t.co/JCH30pi4Vf
The masses have returned to ACR22, a live, face-to-face, and virtual, meeting that began Saturday in Philadelphia. There were hassles and glitches, yet the education and sessions were as you’d expect with many good presentations worth recapping.
Once in a while, I find an abstract at the ACR meeting that can potentially save lives and be implemented in practice now.   In Abstract #0939, Dr. J Patricia Dhar and colleagues shared data from a pilot study examining a new method to monitor cervical health in African American Women with Systemic Lupus Erythematosus (SLE) using a self-sampling brush to assess cervical cytology and human papilloma virus infection.
RT @RichardPAConway: Boekel et al. Omicron variant assoc lower risk of severe COVID-19 in rheumatic disease than prior v

Richard Conway RichardPAConway

3 years 11 months ago
Boekel et al. Omicron variant assoc lower risk of severe COVID-19 in rheumatic disease than prior variants EXCEPT rituximab treated patients. @RheumNow #ACR22 Abstr#0705 https://t.co/57Boj4SEt5 https://t.co/d2NoX83y5l
RT @RichardPAConway: Mendel et al. Use of TMP-SMX prophylaxis in GPA from MarketScan and Medicaid. Used in <25% treat

Richard Conway RichardPAConway

3 years 11 months ago
Mendel et al. Use of TMP-SMX prophylaxis in GPA from MarketScan and Medicaid. Used in <25% treated with RTX!? Female sex negatively assoc (OR 0.61)!? Steroid use in month prior associated (OR 4.31) @RheumNow #ACR22 Abstr#1071 https://t.co/56a0nHR8o4 https://t.co/5LygdFMrss
RT @RichardPAConway: Kifayat et al. Response to Shingrix in rheumatic disease patients. 3/3 PsA, 5/6 SLE, 2/14 RA pts re

Richard Conway RichardPAConway

3 years 11 months ago
Kifayat et al. Response to Shingrix in rheumatic disease patients. 3/3 PsA, 5/6 SLE, 2/14 RA pts reached protective level of 150U/ml. IgG titres and SI are 3x lower compared to non-rheumatic patients. @RheumNow #ACR22 Abstr#0800 https://t.co/Gm7ldxK5xd https://t.co/BlHuU2Jxk2
RT @drdavidliew: I was schooled for exams, testing fine motor function with a buttonhole: felt contrived.

Imagine an el

David Liew drdavidliew

3 years 11 months ago
I was schooled for exams, testing fine motor function with a buttonhole: felt contrived. Imagine an electrical glove for RA pts, doing functional assessment properly Italian study: engineered glove data + HAQ correlates with DAS28 Consistent/scalable! ABST0904 #ACR22 @RheumNow https://t.co/4ZR0An5N9j
RT @RichardPAConway: Martínez-López et al. Higher rates of elevated transaminases with DMARD in those who previously h

Richard Conway RichardPAConway

3 years 11 months ago
Martínez-López et al. Higher rates of elevated transaminases with DMARD in those who previously had abnormal transaminases with isoniazid. @RheumNow #ACR22 Abstr#0816 https://t.co/xiL6DPPcw3 https://t.co/jjxRoEr8iM
RT @RichardPAConway: Khidir et al. Lower educational level increases risk of progression of clinical suspect arthralgia

Richard Conway RichardPAConway

3 years 11 months ago
Khidir et al. Lower educational level increases risk of progression of clinical suspect arthralgia to inflammatory arthritis. HR 2.35 and 5.72 in 2 cohorts. not explained by smoking, BMI or a delay in seeking medical care @RheumNow #ACR22 Abstr#0704 https://t.co/B4bm2Ihapx https://t.co/Veks0WpHLR
RT @ericdeinmd: Ab1042 #ACR22 Ixekizumab Long-term Safety
A Deodhar: Pooled 25 studies for PsO, PsA, AS

5.4 pooled AE p

Eric Dein ericdeinmd

3 years 11 months ago
Ab1042 #ACR22 Ixekizumab Long-term Safety A Deodhar: Pooled 25 studies for PsO, PsA, AS 5.4 pooled AE per 100-patient/year 0.5 IBD per 100-PY 1.3 Oral candidiasis per 100-PY Re-assuring safety numbers. Deodhar: "These are numbers to use in clinical practice" @RheumNow
Data presented at ACR22 shows that cycling through TNFi in axSpA patients with primary lack of efficacy with first line TNFi has limited additional benefit in controlling disease. 
RT @RichardPAConway: Hamroun et al. Unfavourable pregnancy outcomes associated age, nulliparity, steroids in RA. Can onl

Richard Conway RichardPAConway

3 years 11 months ago
Hamroun et al. Unfavourable pregnancy outcomes associated age, nulliparity, steroids in RA. Can only modulate the final one! @RheumNow #ACR22 Abstr#0955 https://t.co/Vob1GeMN25 https://t.co/CsVshIzp8a
RT @AurelieRheumo: de Hooge &amp; al: parameters assoc w/ risk of developing syndesmophytes at 2 yrs in PsA:

Radiograph

Aurelie Najm AurelieRheumo

3 years 11 months ago
de Hooge & al: parameters assoc w/ risk of developing syndesmophytes at 2 yrs in PsA: Radiographic SI according to mNY = 30x higher risk If Rx SI + CRP>6 = 100% risk devlpmt syndesmophytes @ 2 yrs. https://t.co/CR0LymrQdr Abs#1014 #ACR22 @Rheumnow #ACRBest https://t.co/TLWYCJ0eYi
RT @RichardPAConway: Rouhi @Janetbirdope et al RS3PE post checkpoint inhibitor. 11 cases. Can flare after checkpoint inh

Richard Conway RichardPAConway

3 years 11 months ago
Rouhi @Janetbirdope et al RS3PE post checkpoint inhibitor. 11 cases. Can flare after checkpoint inhibitor reintroduction and occur following treatment. @RheumNow #ACR22 Abstr#0758 https://t.co/KCzdJvD0da https://t.co/WQ4eB2hz1k
×